Additionally, to exclude the involvement of other cancer-predisposing genes in the MLH1 p.Leu676Pro carrier, we tested 14 additional cancer-predisposing genes using a gene panel containing 17 genes (MLH1, MSH2, MSH6, ATM, BRCA1, BRCA2, CDKN2A, CHEK2, CTNNB1, ECAD, FANCJ, NBN, PALB2, PTEN, RAD50, RAD51 and TP53) by next-generation sequencing (NGS). This evidence concerns the gene BRCA2 and cancer.